SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Precision BioSciences, Inc. (DTIL) News

Follow Precision BioSciences, Inc. (DTIL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol DTIL Asset equity Sector Markets 90 days 6 Last 7.395 Updated Nov 05, 2026, 12:11 PM UTC Open live news feed Open DTIL chart & news
M Precision BioSciences Prices $125 Million Stock and Warrant Offering EQUITY | Nov 05, 2026, 12:11 PM UTC M Precision Biosciences Reports Third-Quarter 2026 Results Revenue was $0 versus $13K a year earlier. Net loss narrowed to $7.6M from $21.8M, including a $12.7M non-cash gain from changes in warrant fair value. Diluted EPS was $(0.28), compared with $(1.84). EQUITY | Nov 03, 2026, 01:19 PM UTC M Precision BioSciences Reports Q3 Loss Precision BioSciences reported a loss for the third quarter. EQUITY | Nov 03, 2026, 12:12 PM UTC M Precision BioSciences Reports Third-Quarter 2026 Results and Business Update The company says PBGENE-HBV will have a late-breaking oral presentation for the ELIMINATE-B trial at AASLD’s The Liver Meeting; the body truncates before providing the year. EQUITY | Nov 03, 2026, 12:03 PM UTC M Precision Bio doses first patient in Phase 1/2 FUNCTION-DMD trial DTIL Precision Biosciences dosed the first patient in August in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy, targeting up to 60% of patients. EQUITY | Aug 24, 2026, 10:37 AM UTC M Precision BioSciences begins dosing in Phase 1/2 FUNCTION-DMD study Precision BioSciences says it has commenced dosing in its Phase 1/2 FUNCTION-DMD study. EQUITY | Aug 24, 2026, 10:03 AM UTC L DTIL Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Miles DTIL Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones EQUITY | Jul 27, 2026, 11:01 AM UTC L Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Tria Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating EQUITY | Jul 01, 2026, 11:27 AM UTC